{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:05:13Z","timestamp":1791173113602,"version":"4.1.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines.<\/jats:p>","DOI":"10.1016\/j.ejheart.2005.07.002","type":"journal-article","created":{"date-parts":[[2005,8,7]],"date-time":"2005-08-07T09:47:55Z","timestamp":1123408075000},"page":"710-721","source":"Crossref","is-referenced-by-count":95,"title":["Practical Recommendations for the Use of ACE Inhibitors, Beta-Blockers, Aldosterone Antagonists and Angiotensin Receptor Blockers in Heart Failure: Putting Guidelines into Practice"],"prefix":"10.1093","volume":"7","author":[{"given":"John","family":"McMurray","sequence":"first","affiliation":[{"name":"Department of Cardiology, Western Infirmary , Glasgow, G12 8QQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"Hopital Beaujon , Clichy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Dietz","sequence":"additional","affiliation":[{"name":"Franz-Volhard-Klinik , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Eichhorn","sequence":"additional","affiliation":[{"name":"VA Hospital , Dallas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Erhardt","sequence":"additional","affiliation":[{"name":"University Hospital , Malmo ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.D. Richard","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Department of Primary Care and General Practice , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[{"name":"Departments of Epidemiology and Preventive Medicine and Medicine, Monash University\/Alfred Hospital , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Maggioni","sequence":"additional","affiliation":[{"name":"Research Centre, ANMCO , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"McKelvie","sequence":"additional","affiliation":[{"name":"Division of Cardiology, McMaster University , Hamilton ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana L.","family":"Pi\u00f1a","sequence":"additional","affiliation":[{"name":"Case Western Reserve University , Cleveland, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Soler-Soler","sequence":"additional","affiliation":[{"name":"University General Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sahlgrenska University Hospital\/\u00d6stra, Sahlgrenska Academy at G\u00f6teborg University , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,8,7]]},"reference":[{"key":"2026020203561210100_ejhf2005-07-002-bib-0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001888-200501000-00001","article-title":"Why we must teach evidence-based medicine","volume":"80","author":"Whitcomb","year":"2005","journal-title":"Acad Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0002","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). The CONSENSUS trial study group","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effects of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The Study of Left Ventricular Dysfunction (SOLVD) Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0004","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure. The digitalis investigation group","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0007","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0008","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0009","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0010","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0011","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0012","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0013","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0016","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0017","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0018","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ehj.2004.07.025","article-title":"Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: assessment of Reduction in Mortality and Morbidity (CHARM) programme","volume":"25","author":"O\u2019Meara","year":"2004","journal-title":"Eur Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0019","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0021","volume-title":"Agency for Health Care Policy and Research. Heart Failure: evaluation and care of patients with left-ventricular systolic dysfunction","author":"US Department of Health and Human Services","year":"1994"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0022","first-page":"13","article-title":"Concise guide to the management of heart failure","volume":"5","author":"McMurray","year":"1996","journal-title":"Am J Geriatr Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0023","first-page":"99","article-title":"New Zealand guidelines for the management of chronic heart failure. The National Heart Foundation of New Zealand Cardiac Society of Australia and New Zealand and the Royal New Zealand College of General Practitioners Working Party","volume":"110","year":"1997","journal-title":"N Z Med J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0024","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1071-9164(99)91340-4","article-title":"Heart Failure Society of America (HFSA). Practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction\u2013pharmacological approaches","volume":"5","year":"1999","journal-title":"J Card Fail"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0025","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s003920170187","article-title":"Guidelines for the treatment of chronic heart failure. Issued by the executive committee of the German society of cardiology\u2013heart and circulation research, compiled on behalf of the commission of clinical cardiology in cooperation with pharmaceutic commission of the German physicians\u2019 association","volume":"90","author":"Hoppe","year":"2001","journal-title":"Z Kardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0026","first-page":"459","article-title":"National heart foundation of Australia and cardiac society of Australia and New Zealand chronic heart failure clinical practice guidelines Writing Panel. Guidelines for management of patients with chronic heart failure in Australia","volume":"174","author":"Krum","year":"2001","journal-title":"Med J Aust"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0027","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0735-1097(01)01683-7","article-title":"ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to revise the Guidelines for the Evaluation and Management of Heart Failure)","volume":"38","author":"Hunt","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0028","first-page":"347","article-title":"The 2002\/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure","volume":"19","author":"Liu","year":"2003","journal-title":"Can J Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0029","volume-title":"Clinical Guideline 5. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care","author":"National Institute for Clinical Excellence (NICE)","year":"2003"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0030","first-page":"609","article-title":"Guideline \u2018Chronic heart failure\u2014","volume":"148","author":"Mosterd","year":"2004","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"11","key":"2026020203561210100_ejhf2005-07-002-bib-0031","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0032","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2165\/00003495-200161140-00002","article-title":"Underutilisation of ACE inhibitors in patients with congestive heart failure","volume":"61","author":"Bungard","year":"2001","journal-title":"Drugs"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0033","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1053\/euhj.2000.2170","article-title":"European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF)","volume":"21","author":"Hobbs","year":"2000","journal-title":"Eur Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0034","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/S0140-6736(02)11601-1","article-title":"Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey","volume":"360","author":"Cleland","year":"2002","journal-title":"Lancet"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","article-title":"The EuroHeart failure survey programme-a survey on the quality of care among patients with heart failure in Europe: Part 2. Treatment","volume":"24","author":"Komajda","year":"2003","journal-title":"Eur Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0036","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0037","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/bmj.327.7424.1141","article-title":"Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study","volume":"327","author":"Svensson","year":"2003","journal-title":"Br Med J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0038","first-page":"77","article-title":"Prevalence, aetiology and management of heart failure in general practice","volume":"46","author":"Mair","year":"1996","journal-title":"Br J Gen Pract"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0039","first-page":"7","article-title":"Why are angiotensin converting enzyme inhibitors underutilized in the treatment of heart failure by general practitioners=","volume":"59","author":"Houghton","year":"1997","journal-title":"In JK Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0040","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0002-9149(97)89177-1","article-title":"Patterns of angiotensin-converting enzyme inhibitors use in congestive heart failure in two community hospitals","volume":"77","author":"Philbin","year":"1996","journal-title":"Am J Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0041","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/archinte.158.10.1074","article-title":"Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995","volume":"158","author":"Smith","year":"1998","journal-title":"Arch Intern Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0042","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0735-1097(97)00214-3","article-title":"Treatment of patients admitted to the hospital with congestive heart failure: speciality-related disparities in practice patterns and outcomes","volume":"30","author":"Reis","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0043","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ehj.2004.06.006","article-title":"Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey","volume":"25","author":"Lenzen","year":"2004","journal-title":"Eur Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0044","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2710.2003.00531.x","article-title":"Undertreatment of congestive heart failure in an Australian setting","volume":"29","author":"Boyles","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0045","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.0000138934.28340.ED","article-title":"National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction","volume":"110","author":"Masoudi","year":"2004","journal-title":"Circulation"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0046","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ejheart.2004.03.011","article-title":"Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe","volume":"6","author":"Muntwyler","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0047","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/hrt.2003.029553","article-title":"National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland","volume":"90","author":"Murphy","year":"2004","journal-title":"Heart"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0048","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/qjmed\/hci019","article-title":"Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey","volume":"98","author":"Roman-Sanchez","year":"2005","journal-title":"QJM"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0049","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5694\/j.1326-5377.2001.tb143369.x","article-title":"Chronic heart failure in Australian general practice. The Cardiac Awareness Survey And Evaluation (CASE) Study","volume":"174","author":"Krum","year":"2001","journal-title":"Med J Aust"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0050","first-page":"11","article-title":"Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel study","author":"Kasje","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0051","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ahj.2004.06.008","article-title":"Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project","volume":"149","author":"Rathore","year":"2005","journal-title":"Am Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0052","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ejheart.2004.02.004","article-title":"Austrian survey of treating heart failure\u2014AUSTRIA","volume":"6","author":"Fruhwald","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0053","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ahj.2004.04.002","article-title":"Time trends in the use of beta-blockers and other pharmacotherapies in older adults with congestive heart failure","volume":"148","author":"Smith","year":"2004","journal-title":"Am Heart J"},{"issue":"Suppl L","key":"2026020203561210100_ejhf2005-07-002-bib-0054","first-page":"L15","article-title":"Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors=","volume":"19","author":"McMurray","year":"1998","journal-title":"Eur Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0055","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern=","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0056","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMp048144","article-title":"Treatment of heart failure with spironolactone \u2014 trial and tribulations","volume":"351","author":"McMurray","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0057","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2125.2004.02187.x","article-title":"Tolerability of spironolactone in patients with chronic heart failure \u2014 a cautionary message","volume":"58","author":"Witham","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0058","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","article-title":"Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure","volume":"148","author":"Tamirisa","year":"2004","journal-title":"Am Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0059","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1388-9842(01)00173-8","article-title":"Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice","volume":"3","author":"McMurray","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0060","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.jacc.2004.01.041","article-title":"Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge","volume":"43","author":"Butler","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0061","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/heart.89.3.299","article-title":"Beta blockers in patients with congestive heart failure: guided use in clinical practice Investigators. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience","volume":"89","author":"Maggioni","year":"2003","journal-title":"Heart"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0062","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/pds.809","article-title":"Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000","volume":"12","author":"Pont","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0063","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1388-9842(03)00050-3","article-title":"Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice","volume":"5","author":"Rutten","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0064","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1388-9842(03)00003-5","article-title":"Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians","volume":"5","author":"McKee","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0065","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1016\/S0002-8703(03)00315-6","article-title":"Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds\u2014the TEMISTOCLE study","volume":"146","author":"Di Lenarda","year":"2003","journal-title":"Am Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0066","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ahj.2004.04.006","article-title":"Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry","volume":"148","author":"Franciosa","year":"2004","journal-title":"Am Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0067","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2003.04.027","article-title":"A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns","volume":"95","author":"Rywik","year":"2004","journal-title":"Int J Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0068","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1388-9842(03)00055-2","article-title":"Determinants of failure to prescribe target doses of angiotensin-converting enzyme inhibitors for heart failure","volume":"5","author":"Manyemba","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0069","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5694\/j.1326-5377.2005.tb06710.x","article-title":"Barriers to diagnosing and managing heart failure in primary care","volume":"182","author":"Bennett","year":"2005","journal-title":"Med J Aust"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0070","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0071","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0195-668X(03)00112-X","article-title":"Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: results from a prospective, randomised trial","volume":"24","author":"Stromberg","year":"2003","journal-title":"Eur Heart J"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0072","volume-title":"Improving outcomes in chronic heart failure","author":"Blue","year":"2004","edition":"second edition"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0073","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1067\/mhl.2003.5","article-title":"Can treatment with angiotensin-converting enzyme inhibitors in elderly patients with moderate to severe chronic heart failure be improved by a nurse-monitored structured care program= A randomized controlled trial","volume":"32","author":"Ekman","year":"2003","journal-title":"Heart Lung"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0074","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.164.7.769","article-title":"The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes","volume":"164","author":"Tandon","year":"2004","journal-title":"Arch Intern Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0075","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/01.CIR.0000070952.08969.5B","article-title":"Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure","volume":"107","author":"Ansari","year":"2003","journal-title":"Circulation"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0076","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.amjcard.2004.07.083","article-title":"Importance of in-hospital initiation of evidence-based medical therapies for heart failure \u2014 a review","volume":"94","author":"Fonarow","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0077","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ejheart.2004.09.009","article-title":"Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents","volume":"7","author":"Jain","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0078","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejheart.2005.01.005","article-title":"How much responsibility should heart failure nurses take=","volume":"7","author":"Blue","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0079","first-page":"810","article-title":"Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials","volume":"44","author":"McAlister","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0080","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine\u2013isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0081","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"2026020203561210100_ejhf2005-07-002-bib-0082","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00019053-199915060-00002","article-title":"Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing","volume":"15","author":"Andersson","year":"1999","journal-title":"Pharmacoeconomics"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2005.07.002","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/7\/5\/710\/66637917\/eurjhf_7_5_710.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/7\/5\/710\/66637917\/eurjhf_7_5_710.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:56:28Z","timestamp":1770022588000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/7\/5\/710\/8445114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":82,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,8,7]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2005.07.002","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,8]]},"published":{"date-parts":[[2005,8,1]]}}}